Pharming Group N.V. (PHAR)
USD 7.66
(-0.39%)
USD 7.66
(-0.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.87 Million USD | -108.7% |
| 2022 | 33.53 Million USD | -29.97% |
| 2021 | 48.77 Million EUR | -49.45% |
| 2020 | 92.11 Million EUR | 22.14% |
| 2019 | 71.45 Million EUR | 47.92% |
| 2018 | 50.98 Million EUR | 228.05% |
| 2017 | -39.81 Million EUR | -185.48% |
| 2016 | -13.87 Million EUR | 5.43% |
| 2015 | -14.74 Million EUR | -496.72% |
| 2014 | 3.71 Million EUR | 123.48% |
| 2013 | -15.83 Million EUR | 39.02% |
| 2012 | -25.96 Million EUR | -7.59% |
| 2011 | -24.13 Million EUR | 48.05% |
| 2010 | -46.45 Million EUR | -39.53% |
| 2009 | -33.29 Million EUR | 1.19% |
| 2008 | -33.69 Million EUR | 29.65% |
| 2007 | -47.89 Million EUR | -131.34% |
| 2006 | -21.17 Million EUR | -4.23% |
| 2005 | -19.86 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.71 Million USD | -240.23% |
| 2024 Q2 | -4.28 Million USD | 55.51% |
| 2024 Q3 | 7.71 Million USD | 269.35% |
| 2023 FY | - USD | -108.7% |
| 2023 Q1 | -11.57 Million USD | 2.27% |
| 2023 Q4 | 8.22 Million USD | 4.59% |
| 2023 Q2 | 6.72 Million USD | 158.08% |
| 2023 Q3 | 7.86 Million USD | 16.94% |
| 2022 Q3 | 12.48 Million USD | -45.69% |
| 2022 FY | - USD | -29.97% |
| 2022 Q2 | 22.98 Million USD | 194.54% |
| 2022 Q1 | 7.8 Million USD | -43.87% |
| 2022 Q4 | -11.84 Million USD | -194.88% |
| 2021 Q1 | 15.92 Million EUR | -36.74% |
| 2021 Q2 | 11.16 Million EUR | -29.91% |
| 2021 Q3 | 4.48 Million EUR | -59.8% |
| 2021 FY | - EUR | -49.45% |
| 2021 Q4 | 13.89 Million EUR | 209.72% |
| 2020 FY | - EUR | 22.14% |
| 2020 Q1 | 23.75 Million EUR | 9.89% |
| 2020 Q4 | 25.17 Million EUR | -17.77% |
| 2020 Q3 | 30.61 Million EUR | 143.67% |
| 2020 Q2 | 12.56 Million EUR | -47.09% |
| 2019 Q2 | 16.79 Million EUR | 9.78% |
| 2019 FY | - EUR | 47.92% |
| 2019 Q1 | 15.3 Million EUR | 42.69% |
| 2019 Q3 | 21.7 Million EUR | 29.2% |
| 2019 Q4 | 21.61 Million EUR | -0.4% |
| 2018 FY | - EUR | 228.05% |
| 2018 Q4 | 10.72 Million EUR | -47.2% |
| 2018 Q3 | 20.3 Million EUR | 171.31% |
| 2018 Q2 | 7.48 Million EUR | -39.94% |
| 2018 Q1 | 12.46 Million EUR | 116.49% |
| 2017 FY | - EUR | -185.48% |
| 2017 Q2 | -28.06 Million EUR | -467.94% |
| 2017 Q3 | 56.19 Million EUR | 300.25% |
| 2017 Q4 | -75.57 Million EUR | -234.49% |
| 2017 Q1 | 7.62 Million EUR | 320.69% |
| 2016 Q3 | -3.42 Million EUR | -6.25% |
| 2016 FY | - EUR | 5.43% |
| 2016 Q1 | -3.83 Million EUR | -605.74% |
| 2016 Q4 | -3.45 Million EUR | -0.83% |
| 2016 Q2 | -3.22 Million EUR | 15.94% |
| 2015 Q2 | -3.5 Million EUR | -6.12% |
| 2015 FY | - EUR | -496.72% |
| 2015 Q1 | -3.29 Million EUR | -162.49% |
| 2015 Q4 | -543.74 Thousand EUR | 84.04% |
| 2015 Q3 | -3.4 Million EUR | 2.66% |
| 2014 Q1 | -4.2 Million EUR | 63.94% |
| 2014 FY | - EUR | 123.48% |
| 2014 Q4 | 5.27 Million EUR | 209.63% |
| 2014 Q2 | -3.05 Million EUR | 27.24% |
| 2014 Q3 | -4.81 Million EUR | -57.41% |
| 2013 FY | - EUR | 39.02% |
| 2013 Q1 | -2.09 Million EUR | 63.56% |
| 2013 Q2 | 1.62 Million EUR | 177.19% |
| 2013 Q4 | -11.66 Million EUR | -215.59% |
| 2013 Q3 | -3.69 Million EUR | -328.06% |
| 2012 Q3 | -7.19 Million EUR | 13.93% |
| 2012 FY | - EUR | -7.59% |
| 2012 Q1 | -6.14 Million EUR | -73.42% |
| 2012 Q4 | -5.75 Million EUR | 19.92% |
| 2012 Q2 | -8.35 Million EUR | -36.03% |
| 2011 Q2 | -6.65 Million EUR | -9.73% |
| 2011 Q3 | -6.58 Million EUR | 0.96% |
| 2011 Q4 | -3.54 Million EUR | 46.25% |
| 2011 FY | - EUR | 48.05% |
| 2011 Q1 | -6.06 Million EUR | 75.18% |
| 2010 FY | - EUR | -39.53% |
| 2010 Q4 | -24.42 Million EUR | -304.2% |
| 2010 Q3 | -6.04 Million EUR | 3.94% |
| 2010 Q2 | -6.29 Million EUR | 21.32% |
| 2010 Q1 | -7.99 Million EUR | 4.92% |
| 2009 Q4 | -8.41 Million EUR | 6.56% |
| 2009 Q3 | -9 Million EUR | -35.35% |
| 2009 Q2 | -6.65 Million EUR | 22.37% |
| 2009 Q1 | -8.56 Million EUR | 0.0% |
| 2009 FY | - EUR | 1.19% |
| 2008 FY | - EUR | 29.65% |
| 2007 FY | - EUR | -131.34% |
| 2006 FY | - EUR | -4.23% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 105.14% |
| Alkermes plc | 495.04 Million USD | 98.005% |
| Agenus Inc. | -145.92 Million USD | 106.769% |
| Aptorum Group Limited | -9.59 Million USD | 202.896% |
| Ardelyx, Inc. | -55.35 Million USD | 117.843% |
| Dyadic International, Inc. | -8.22 Million USD | 220.016% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 3494.158% |
| Lantern Pharma Inc. | -15.78 Million USD | 162.565% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 149.602% |
| Novavax, Inc. | -487.39 Million USD | 102.027% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 113.907% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 112.583% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 154.953% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 199.087% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 117.215% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 102.599% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 140.963% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -1767.108% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 106.283% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 113.202% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 148.995% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 141.614% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 142.835% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 108.089% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 103.825% |
| AlloVir, Inc. | -190.14 Million USD | 105.194% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 105.622% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 133.758% |
| Bicycle Therapeutics plc | -183.4 Million USD | 105.385% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 105.971% |
| ChromaDex Corporation | -3.89 Million USD | 353.647% |
| Chimerix, Inc. | -92.97 Million USD | 110.623% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 122.227% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 108.777% |
| CRISPR Therapeutics AG | -202.7 Million USD | 104.873% |
| Precision BioSciences, Inc. | -32.04 Million USD | 130.825% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 105.735% |
| Fortress Biotech, Inc. | -133.64 Million USD | 107.391% |
| Fortress Biotech, Inc. | -133.64 Million USD | 107.391% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 112.77% |
| ImmuCell Corporation | -2.5 Million USD | 494.437% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 107.573% |
| Immix Biopharma, Inc. | -16.13 Million USD | 161.212% |
| Incyte Corporation | 919.42 Million USD | 98.926% |
| Innoviva, Inc. | 248.96 Million USD | 96.033% |
| IO Biotech, Inc. | -91.22 Million USD | 110.827% |
| Jaguar Health, Inc. | -33.13 Million USD | 129.812% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 106.49% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 90.291% |
| ContextLogic Inc. | -324 Million USD | 103.048% |
| MiMedx Group, Inc. | 40.51 Million USD | 75.623% |
| MEI Pharma, Inc. | 26.38 Million USD | 62.559% |
| NextCure, Inc. | -59.03 Million USD | 116.73% |
| Onconetix, Inc. | -36.7 Million USD | 126.908% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -341.924% |
| Opthea Limited | -200.01 Million USD | 104.938% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 458.957% |
| Vaxcyte, Inc. | -464.88 Million USD | 102.125% |
| PDS Biotechnology Corporation | -40.08 Million USD | 124.64% |
| Precigen, Inc. | -89.22 Million USD | 111.07% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 106.21% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 143.392% |
| PureTech Health plc | -11.62 Million USD | 184.949% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 158.165% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 104.23% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 140.963% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 111.297% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 134.102% |
| Acelyrin, Inc. | -381.52 Million USD | 102.589% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 76755.68% |
| Summit Therapeutics Inc. | 1 Million USD | -886.713% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 129.584% |
| Senti Biosciences, Inc. | -61.33 Million USD | 116.103% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 108.795% |
| Elevation Oncology, Inc. | -41.46 Million USD | 123.819% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 131.96% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 261.48% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 3176.947% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 130.435% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 217.639% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 116.8% |
| Seer, Inc. | -97.88 Million USD | 110.09% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 115.88% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 115.111% |
| ESSA Pharma Inc. | -26.45 Million USD | 137.335% |
| GlycoMimetics, Inc. | -39.12 Million USD | 125.247% |
| GT Biopharma, Inc. | 5.97 Million USD | -65.195% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 104.779% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 243.812% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 88.623% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 117.403% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 119.284% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 199.9% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 101.829% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 243.478% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 121.077% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 104.174% |
| Aptose Biosciences Inc. | -52.26 Million USD | 118.897% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 109.167% |
| Soligenix, Inc. | -7.85 Million USD | 225.776% |
| Century Therapeutics, Inc. | -121.2 Million USD | 108.149% |
| Kura Oncology, Inc. | -164.95 Million USD | 105.988% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 112.331% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 197.928% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 1131.283% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 329.218% |
| Autolus Therapeutics plc | -156.77 Million USD | 106.3% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 111.667% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 114.314% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 149.549% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 105.218% |
| GRI Bio, Inc. | -10.89 Million USD | 190.631% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 318.725% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 108.062% |
| IGM Biosciences, Inc. | -253.35 Million USD | 103.898% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 109.516% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 125.901% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 164.425% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 162.738% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 117.375% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 109.222% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 103.713% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 105.093% |
| Verastem, Inc. | -83.16 Million USD | 111.876% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 119.531% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 106.242% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 108.657% |
| Histogen Inc. | -10.5 Million USD | 194.04% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 169.168% |
| Surrozen, Inc. | -41.13 Million USD | 124.014% |
| Organovo Holdings, Inc. | -14.8 Million USD | 166.709% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -307882.538% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 116.822% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 119.256% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 145.856% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 218.458% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 105.948% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 120.051% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 140.871% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 165.606% |
| Apollomics, Inc. | -171.74 Million USD | 105.751% |
| Amarin Corporation plc | -50.9 Million USD | 119.404% |
| Mesoblast Limited | -61.33 Million USD | 116.104% |
| Turnstone Biologics Corp. | -56.23 Million USD | 117.564% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 106.897% |
| Synaptogenix, Inc. | -8.3 Million USD | 218.892% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 164.391% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 115.666% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 306.137% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -2202.122% |
| Exelixis, Inc. | 196.6 Million USD | 94.976% |
| Better Therapeutics, Inc. | -38.26 Million USD | 125.814% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 106.985% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 101.995% |
| NLS Pharmaceutics AG | -11.79 Million USD | 183.734% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -3895.292% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 133.475% |
| Gritstone bio, Inc. | -126.86 Million USD | 107.786% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 115.199% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 346.928% |
| Avid Bioservices, Inc. | -11.48 Million USD | 186.029% |
| Insmed Incorporated | -654.73 Million USD | 101.509% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 539.033% |
| MediWound Ltd. | -4.89 Million USD | 301.86% |
| OmniAb, Inc. | -49.73 Million USD | 119.861% |
| Alector, Inc. | -142.89 Million USD | 106.912% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 111.561% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 118.94% |
| Zai Lab Limited | -366.57 Million USD | 102.694% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 103.398% |
| Aura Biosciences, Inc. | -83.69 Million USD | 111.801% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 104.385% |
| Immunic, Inc. | -99.11 Million USD | 109.965% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 107.501% |
| Veracyte, Inc. | -49.4 Million USD | 119.99% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 239.823% |
| FibroGen, Inc. | -261.4 Million USD | 103.778% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 188.655% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 241.073% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 152.771% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 99.319% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 138.852% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 75.239% |
| TG Therapeutics, Inc. | 26.1 Million USD | 62.157% |
| Galecto, Inc. | -37.51 Million USD | 126.325% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 125.812% |
| Fortrea Holdings Inc. | 167.3 Million USD | 94.096% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 107.356% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 134.887% |
| XBiotech Inc. | -35.76 Million USD | 127.616% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 115.199% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 115.137% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 109.456% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 138.474% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 124.169% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 101.912% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 117.631% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 17721.452% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 108.49% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 144.552% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 104.202% |
| NexImmune, Inc. | -28.16 Million USD | 135.065% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 278.752% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 183.758% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 99.788% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 138.898% |
| Scopus BioPharma Inc. | -11.71 Million USD | 184.324% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 107.848% |
| Ainos, Inc. | -8.77 Million USD | 212.583% |
| Pluri Inc. | -20.22 Million USD | 148.836% |
| Prothena Corporation plc | -190.1 Million USD | 105.195% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 107.704% |
| Celularity Inc. | -183.94 Million USD | 105.37% |
| Rallybio Corporation | -72.37 Million USD | 113.647% |
| Cue Biopharma, Inc. | -46.05 Million USD | 121.447% |
| MeiraGTx Holdings plc | -57.05 Million USD | 117.312% |
| Omeros Corporation | -163.61 Million USD | 106.037% |
| Humacyte, Inc. | -96.45 Million USD | 110.24% |
| Immunocore Holdings plc | -59.64 Million USD | 116.559% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 150.986% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 140.538% |
| Blueprint Medicines Corporation | -474.61 Million USD | 102.081% |
| CalciMedica, Inc. | -34.18 Million USD | 128.889% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 113.487% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 107.87% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 105.863% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 103.913% |
| Pulmatrix, Inc. | -12.64 Million USD | 178.104% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 129.961% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 111.165% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 101.951% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 109.758% |
| Cytokinetics, Incorporated | -456.68 Million USD | 102.163% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 129.596% |
| Nutriband Inc. | -5.12 Million USD | 292.843% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 122.825% |
| Vor Biopharma Inc. | -114.37 Million USD | 108.636% |
| Roivant Sciences Ltd. | -996.51 Million USD | 100.991% |
| Evogene Ltd. | -23.2 Million USD | 142.566% |
| ProKidney Corp. | -147.66 Million USD | 106.689% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 115.305% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 6549.275% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 101.747% |
| CorMedix Inc. | -48.88 Million USD | 120.204% |
| BioLineRx Ltd. | -57.06 Million USD | 117.31% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 108.838% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 4989.604% |
| Atai Life Sciences N.V. | -36.31 Million USD | 127.201% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 112.421% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 112.147% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 103.585% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 132.131% |
| MediciNova, Inc. | -9.87 Million USD | 199.97% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 107.843% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 745.471% |
| GeoVax Labs, Inc. | -26.66 Million USD | 137.036% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 104.39% |
| Biomea Fusion, Inc. | -124.62 Million USD | 107.926% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 102.99% |
| Mereo BioPharma Group plc | -26.05 Million USD | 137.907% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 105.189% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 104.295% |
| Absci Corporation | -95.45 Million USD | 110.347% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 132.896% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 109.221% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 104.23% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 143.216% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 104.752% |
| Allakos Inc. | -189.91 Million USD | 105.201% |
| Imunon, Inc. | -19.87 Million USD | 149.687% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 109.104% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 90.882% |
| BioAtla, Inc. | -122.24 Million USD | 108.08% |
| NLS Pharmaceutics AG | -11.79 Million USD | 183.734% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 162.667% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 103.289% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 123.83% |
| XOMA Corporation | -39.36 Million USD | 125.093% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 109.951% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 108.395% |
| aTyr Pharma, Inc. | -52.17 Million USD | 118.929% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 111.784% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 106.645% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 104.211% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 172.343% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 222.813% |
| Akari Therapeutics, Plc | -16.8 Million USD | 158.785% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -5134.068% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 97.815% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 254.603% |
| UroGen Pharma Ltd. | -63.83 Million USD | 115.474% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 114.543% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 235.99% |
| Orgenesis Inc. | -60.71 Million USD | 116.267% |
| Entera Bio Ltd. | -8.8 Million USD | 212.188% |
| GH Research PLC | -41.15 Million USD | 124.001% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 138.704% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 112.011% |
| Xencor, Inc. | -125.87 Million USD | 107.847% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 792.372% |
| Replimune Group, Inc. | -230.19 Million USD | 104.291% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 148.999% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 190.267% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 254.603% |
| Portage Biotech Inc. | -18.19 Million USD | 154.272% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 745.471% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 109.444% |
| OncoCyte Corporation | -23.12 Million USD | 142.715% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 187.404% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 186.211% |
| Purple Biotech Ltd. | -22.22 Million USD | 144.441% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 254.087% |
| scPharmaceuticals Inc. | -46.06 Million USD | 121.443% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 155.459% |
| HilleVax, Inc. | -132.46 Million USD | 107.456% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 192.89% |
| Tharimmune, Inc. | -9.3 Million USD | 206.175% |
| Genprex, Inc. | -31.06 Million USD | 131.799% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 105.267% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 131.502% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 1392.801% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -6445.221% |
| OKYO Pharma Limited | -15.74 Thousand USD | 62827.56% |
| Savara Inc. | -59.13 Million USD | 116.703% |
| Curis, Inc. | -45.13 Million USD | 121.881% |
| Daré Bioscience, Inc. | -30.7 Million USD | 132.171% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 165.018% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 237.851% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 136.945% |
| BeiGene, Ltd. | -1.12 Billion USD | 100.878% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 160.591% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 102.294% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 110.933% |
| Erasca, Inc. | -121.31 Million USD | 108.142% |
| bluebird bio, Inc. | -167.16 Million USD | 105.909% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 319.55% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 96.817% |
| DBV Technologies S.A. | -85.98 Million USD | 111.487% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 319.55% |
| Moderna, Inc. | -3.28 Billion USD | 100.301% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 123.181% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 274.876% |
| Molecular Templates, Inc. | 1.43 Million USD | -590.699% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 116.502% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 103.027% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 107.205% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 120.853% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 107.104% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 104.798% |
| MacroGenics, Inc. | 2.01 Million USD | -389.688% |
| RenovoRx, Inc. | -11.39 Million USD | 186.716% |
| Adicet Bio, Inc. | -136.53 Million USD | 107.234% |
| Prime Medicine, Inc. | -193.75 Million USD | 105.098% |
| Aditxt, Inc. | -25.45 Million USD | 138.797% |
| Adagene Inc. | -14.95 Million USD | 166.063% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 235.114% |
| Quantum-Si incorporated | -91.8 Million USD | 110.759% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 98.614% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 92.189% |
| SciSparc Ltd. | -5.28 Million USD | 286.994% |
| Vericel Corporation | 2.86 Million USD | -244.867% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 10474.128% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 145.534% |
| Generation Bio Co. | -133.3 Million USD | 107.41% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 111.896% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 111.482% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 104.343% |
| Invivyd, Inc. | -196.61 Million USD | 105.024% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 102.64% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 206.493% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 63.626% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 196.033% |
| 2seventy bio, Inc. | -206.41 Million USD | 104.785% |
| ADMA Biologics, Inc. | 5.12 Million USD | -92.91% |
| Clene Inc. | -43.24 Million USD | 122.842% |
| Capricor Therapeutics, Inc. | -23 Million USD | 142.927% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 120.375% |
| GeoVax Labs, Inc. | -26.66 Million USD | 137.036% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 103.297% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 126.891% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 58.1% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -101.15% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 130.408% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 106.235% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 101.443% |
| Evaxion Biotech A/S | -21.4 Million USD | 146.148% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 114.872% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 104.538% |
| Trevena, Inc. | -35.28 Million USD | 127.99% |
| Surrozen, Inc. | -41.13 Million USD | 124.014% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 112.41% |
| Cingulate Inc. | -22.95 Million USD | 143.033% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 232.382% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 126.492% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 220.065% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 109.658% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 114.562% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 116.921% |
| Clearmind Medicine Inc. | -8.71 Million USD | 213.39% |
| Kronos Bio, Inc. | -121.83 Million USD | 108.107% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 113.286% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 504.561% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 109.796% |
| Statera Biopharma, Inc. | 38.93 Million USD | 74.632% |
| ImmunityBio, Inc. | -436.18 Million USD | 102.264% |
| Korro Bio, Inc. | -80.9 Million USD | 112.208% |
| Kineta, Inc. | -15.71 Million USD | 162.855% |
| BioVie Inc. | -31.95 Million USD | 130.914% |
| Codexis, Inc. | -49.28 Million USD | 120.041% |
| Celularity Inc. | -183.94 Million USD | 105.37% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 104.459% |
| Celcuity Inc. | -58.3 Million USD | 116.939% |
| Virax Biolabs Group Limited | -6.6 Million USD | 249.444% |
| Cibus, Inc. | -314.58 Million USD | 103.14% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 129.28% |
| IN8bio, Inc. | -28.5 Million USD | 134.651% |
| Kodiak Sciences Inc. | -259.02 Million USD | 103.813% |
| Annexon, Inc. | -141.57 Million USD | 106.977% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 108.772% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 115.386% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 135.332% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 104.294% |
| Eyenovia, Inc. | -24.1 Million USD | 140.973% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 77.945% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 3148.457% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 113.383% |
| Arcellx, Inc. | -64.14 Million USD | 115.398% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 121.942% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 107.999% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 131.983% |
| Moolec Science SA | -52.07 Million USD | 118.967% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 119.139% |
| Geron Corporation | -174.78 Million USD | 105.651% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 124.438% |
| Royalty Pharma plc | 1.88 Billion USD | 99.477% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 108.259% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 205.928% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 147.621% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 105.947% |
| Humacyte, Inc. | -96.45 Million USD | 110.24% |
| Structure Therapeutics Inc. | -102.45 Million USD | 109.64% |
| 89bio, Inc. | -134.46 Million USD | 107.346% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 112.522% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -143.756% |
| Genelux Corporation | -24.16 Million USD | 140.873% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 129.222% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 106.042% |
| Notable Labs, Ltd. | -14.4 Million USD | 168.59% |
| Liquidia Corporation | -70.05 Million USD | 114.1% |
| Mustang Bio, Inc. | -48.06 Million USD | 120.55% |
| Immunovant, Inc. | -269.97 Million USD | 103.658% |
| Quantum-Si incorporated | -91.8 Million USD | 110.759% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 113.914% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 151.155% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 109.682% |
| Acasti Pharma Inc. | -11.3 Million USD | 187.399% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 144.385% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 164.425% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 104.692% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 331.293% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 162.198% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 134.324% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 126.673% |
| PepGen Inc. | -83.58 Million USD | 111.817% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 133.477% |
| United Therapeutics Corporation | 1.38 Billion USD | 99.288% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 143.137% |
| Solid Biosciences Inc. | -93.43 Million USD | 110.571% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 306.99% |
| Immuneering Corporation | -58.06 Million USD | 117.011% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -307882.538% |
| Silo Pharma, Inc. | -3.62 Million USD | 372.378% |
| Belite Bio, Inc | -31.52 Million USD | 131.327% |
| XOMA Corporation | -39.36 Million USD | 125.093% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 114.644% |
| Bionomics Limited | -9.83 Million USD | 200.407% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 111.76% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 128.541% |
| uniQure N.V. | -253.1 Million USD | 103.902% |
| Cassava Sciences, Inc. | -95.68 Million USD | 110.322% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 235.114% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 107.627% |
| Forte Biosciences, Inc. | -32.47 Million USD | 130.412% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 222.688% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 135.001% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 3148.457% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 188.655% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 162.116% |
| Altimmune, Inc. | -87.93 Million USD | 111.232% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 110.727% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 128.541% |
| Compugen Ltd. | -12.51 Million USD | 178.915% |
| Peak Bio, Inc. | -1356.23 USD | 728368.804% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 120.324% |
| Benitec Biopharma Inc. | -22.49 Million USD | 143.917% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 104.076% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 134.604% |
| Zura Bio Limited | -60.56 Million USD | 116.309% |
| PolyPid Ltd. | -20.26 Million USD | 148.744% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 163.261% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 134.604% |
| Instil Bio, Inc. | -146.12 Million USD | 106.759% |
| argenx SE | -216.02 Million USD | 104.572% |
| Immunome, Inc. | -28.27 Million USD | 134.937% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 120.376% |
| Verona Pharma plc | -52.46 Million USD | 118.825% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 110.422% |
| Shattuck Labs, Inc. | -87.61 Million USD | 111.273% |
| CervoMed Inc. | -2.17 Million USD | 554.769% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 108.08% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 177.815% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 120.503% |
| Moolec Science SA | -52.07 Million USD | 118.967% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 157.625% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 107.575% |
| AnaptysBio, Inc. | -143.16 Million USD | 106.899% |
| Design Therapeutics, Inc. | -66.32 Million USD | 114.892% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 112.196% |
| NeurAxis, Inc. | -6.66 Million USD | 248.203% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 126.164% |
| Lumos Pharma, Inc. | -36.57 Million USD | 127.008% |
| Achilles Therapeutics plc | -70.44 Million USD | 114.021% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 110.422% |
| 180 Life Sciences Corp. | -22.13 Million USD | 144.624% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -69.439% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 504.561% |
| Nutriband Inc. | -5.12 Million USD | 292.843% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 109.0% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 117.818% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 119.539% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 115.131% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 118.254% |
| Palisade Bio, Inc. | -12.28 Million USD | 180.425% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 121.767% |
| Beam Therapeutics Inc. | -156.47 Million USD | 106.312% |
| Neurogene Inc. | -52.28 Million USD | 118.89% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 107.236% |
| AEON Biopharma, Inc. | -48.36 Million USD | 120.423% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 110.618% |
| Sesen Bio, Inc. | -50.84 Million USD | 119.428% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 112.055% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 179.976% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 102.311% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 109.389% |
| Athira Pharma, Inc. | -116.7 Million USD | 108.463% |
| Vaccinex, Inc. | -19.74 Million USD | 150.015% |
| HCW Biologics Inc. | -23.57 Million USD | 141.894% |
| XOMA Corporation | -39.36 Million USD | 125.093% |
| Nektar Therapeutics | -243.1 Million USD | 104.063% |
| Arvinas, Inc. | -394.8 Million USD | 102.502% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -5134.068% |
| Merus N.V. | -149.2 Million USD | 106.62% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 110.565% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 131.596% |
| Rezolute, Inc. | -68.42 Million USD | 114.435% |
| Clene Inc. | -43.24 Million USD | 122.842% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 164.044% |
| BeyondSpring Inc. | -21.54 Million USD | 145.854% |
| Synlogic, Inc. | -55.16 Million USD | 117.906% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 181.743% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 192.812% |
| Peak Bio, Inc. | -1356.23 USD | 728368.804% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 130.424% |
| Krystal Biotech, Inc. | 17.9 Million USD | 44.834% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 108.34% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 102.894% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 314.418% |
| MannKind Corporation | 15.12 Million USD | 34.715% |
| Ikena Oncology, Inc. | -74.39 Million USD | 113.276% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 178.432% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 51.409% |
| Gossamer Bio, Inc. | -172.15 Million USD | 105.737% |
| CohBar, Inc. | -12.06 Million USD | 181.86% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 138.72% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 132.896% |
| Legend Biotech Corporation | -477.87 Million USD | 102.067% |
| Mural Oncology plc | -192.72 Million USD | 105.125% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 108.66% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 161.176% |
| Disc Medicine, Inc. | -91.02 Million USD | 110.851% |
| Champions Oncology, Inc. | -5.05 Million USD | 295.429% |
| REGENXBIO Inc. | -239.46 Million USD | 104.125% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 192.152% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 117.715% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 125.477% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 108.756% |
| Vaxart, Inc. | -74.72 Million USD | 113.218% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 128.053% |
| Cellectis S.A. | -98.09 Million USD | 110.069% |
| Longeveron Inc. | -20.06 Million USD | 149.237% |
| Repare Therapeutics Inc. | -114.27 Million USD | 108.643% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 102.249% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 113.202% |
| Revolution Medicines, Inc. | -430.58 Million USD | 102.294% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 257.052% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 132.08% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 113.242% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -101.448% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 190.078% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 99.786% |
| Denali Therapeutics Inc. | -179.97 Million USD | 105.488% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 10474.128% |
| Veru Inc. | -89.97 Million USD | 110.977% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 136.748% |
| Cingulate Inc. | -22.95 Million USD | 143.033% |
| Passage Bio, Inc. | -98.34 Million USD | 110.044% |
| Context Therapeutics Inc. | -25.06 Million USD | 139.413% |
| Exicure, Inc. | -15.53 Million USD | 163.563% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 104.793% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 126.712% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 265.649% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 105.863% |
| Nuvalent, Inc. | -149.49 Million USD | 106.607% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 221.452% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 111.499% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 132.729% |
| OmniAb, Inc. | -49.73 Million USD | 119.861% |
| Anew Medical, Inc. | -1.3 Million USD | 859.279% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 179.885% |
| Lipocine Inc. | -16.32 Million USD | 160.511% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 114.815% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 113.293% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 125.901% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 125.317% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 144.525% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 101.812% |
| Ocugen, Inc. | -64.82 Million USD | 115.236% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 110.67% |
| Q32 Bio Inc. | -86.5 Million USD | 111.418% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 158.351% |
| Alumis Inc. Common Stock | -156.89 Million USD | 106.295% |
| Equillium, Inc. | -12.13 Million USD | 181.373% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 116.892% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 224.972% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 152.367% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 121.154% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 109.288% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 155.22% |
| Dominari Holdings Inc. | -22.44 Million USD | 144.015% |
| Edesa Biotech, Inc. | -8.19 Million USD | 220.596% |
| vTv Therapeutics Inc. | -25.41 Million USD | 138.867% |
| Bio-Techne Corporation | 326.66 Million USD | 96.976% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 102.566% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 95.436% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 107.533% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 126.387% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 106.537% |
| Nkarta, Inc. | -120.48 Million USD | 108.198% |
| BioCardia, Inc. | -11.56 Million USD | 185.441% |
| Iterum Therapeutics plc | -34.58 Million USD | 128.563% |